Opendata, web and dolomites

BRIDGES

Bioinformatic approaches to identify and detect both disease- and drug-related genomic alterations in breast cancer patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "BRIDGES" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.cruk.cam.ac.uk/research-groups/caldas-group
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 183˙454.00

Map

 Project objective

Breast cancer is the most common cancer among European women showing high clinical and molecular heterogeneity. Current clinical management causes patients overtreatment with implications on both patients’ quality of life and healthcare costs. Moreover, intrinsic or acquired tumor resistance to treatment leads to incurable metastatic progression in a significant proportion of patients. Advances in cancer genomics highlighted a high inter- and intra-tumor genetic heterogeneity, reinforcing the need for a mutation-based personalized treatment and a way to non-invasively monitor evolving disease. This project will significantly contribute in addressing such unmet challenge aiming 1) to identify altered breast cancer driver pathways, 2) to study their association with drug response and 3) to develop tools for a non-invasive assessment of such alterations. By integrating multi-dimensional molecular data from more than 3000 cases, driver pathways will be identified and their association with previous breast cancer classifications as well as their prognostic significance will be studied. Their predictive power will be investigated in a matchless bio-bank of Patient Derived Xenografts, a much more reliable pre-clinical model, able to recapitulate inter- and intra-tumor heterogeneity observed in patients. Multi-dimensional molecular data and high throughput drug screenings are available and will be integrated to identify novel pharmacogenomics associations. Mining of such amount of data will allow defining a portfolio of relevant breast cancer alterations that will be sought in plasma of patients from the DETECT trial, towards a non-invasive monitoring able to guide therapeutic strategy. Development and application of cutting-edge computational approaches is fundamental to reach above aims and it will constitute a major part of the efforts, considerably expanding Experienced Researcher's know-how in the field of cancer genomics and translational medicine.

 Publications

year authors and title journal last update
List of publications.
2017 Maurizio Callari, Stephen-John Sammut, Leticia De Mattos-Arruda, Alejandra Bruna, Oscar M. Rueda, Suet-Feung Chin, Carlos Caldas
Intersect-then-combine approach: improving the performance of somatic variant calling in whole exome sequencing data using multiple aligners and callers
published pages: , ISSN: 1756-994X, DOI: 10.1186/s13073-017-0425-1
Genome Medicine 9/1 2019-07-24
2016 Alejandra Bruna, Oscar M. Rueda, Wendy Greenwood, Ankita Sati Batra, Maurizio Callari, Rajbir Nath Batra, Katherine Pogrebniak, Jose Sandoval, John W. Cassidy, Ana Tufegdzic-Vidakovic, Stephen-John Sammut, Linda Jones, Elena Provenzano, Richard Baird, Peter Eirew, James Hadfield, Matthew Eldridge, Anne McLaren-Douglas, Andrew Barthorpe, Howard Lightfoot, Mark J. O’Connor, Joe Gray, Javier Cortes, Jose Baselga, Elisabetta Marangoni, Alana L. Welm, Samuel Aparicio, Violeta Serra, Mathew J. Garnett, Carlos Caldas
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds
published pages: 260-274.e22, ISSN: 0092-8674, DOI: 10.1016/j.cell.2016.08.041
Cell 167/1 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIDGES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIDGES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More